Contact HealthDay
Tel: 203.855.1400 or E-mail

News By Specialty

Allergy
Anesthesiology
Cardiology
Cosmetic Surgery
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Practice
Gastroenterology
Geriatrics
Hematology & Oncology
HIV & AIDS
Infectious Disease
Internal Medicine
Nephrology
Neurology
Nursing
OBGYN & Women's Health
Ophthalmology
Orthopedics
Otolaryngology
Pain Management
Pathology
Pediatrics
Pharmacy
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Follow us on:

    


e-Healthcare Leadership Awards


ASN: Bardoxolone Methyl No Benefit in T2DM, Stage 4 CKD
Trial stopped early due to increased rate of cardiovascular events with bardoxolone methyl
This article is older than one year and is no longer available.

Copyright © 2013 HealthDay. All rights reserved.

August 1, 2015

Archive Search

By Keyword:
By Category:
By Topic:

Related Articles

U.S. Health Spending Projected to Rise 5.8 Percent By 2024

Tyrosine Kinase Inhibitors Seem Safe in CML With CKD

FDA Warns of Confusion Between Brintellix, Brilinta

Treatment Targets Not Met by Most Older Patients With Diabetes

Targeted Exercises Can Boost Men's Bone Health

'Thrifty Phenotype' Leads to Less Weight Loss in Obese